



Radicava® (Edaravone) (Intravenous)

Last Review Date: January 1, 2019

Number: MG.MM.PH.121

Medical Guideline Disclaimer

All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Radicava is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- **Initial dose:** 60 billable units (mg) daily for 14 days, followed by 14 days off per 28-day cycle
- **Subsequent doses:** 60 billable units (mg) daily for 10 days out of 14 days, followed by 14 days off per 28-day cycle

Guideline

I. INITIAL APPROVAL CRITERIA

Radicava may be considered medically necessary if one of the below conditions are met **AND** use is consistent with the medical necessity criteria that follows:

Amyotrophic Lateral Sclerosis †

- Patient must have a diagnosis of ALS (disease duration for two years or less)
- Patient must be at least 18 years of age; **AND**
- The medication is being prescribed by a neurologist that specializes in ALS and/or neuromuscular disorders
- The patient has had an inadequate response, intolerance, or contraindication to riluzole (Rilutek)

- The patient has a Baseline ALS Functional Rating Scale-Revised (ALSFRS-R) with a score of 2 or greater on each individual item of the scale
- Normal respiratory function %FVC \geq 80%
- NO severe renal impairment (CrCl less than 30 mL/min) or end stage renal disease
- NO moderate to severe hepatic impairment (Child-Pugh Class C)

† FDA-labeled indication(s)

Limitations/Exclusions

If the above criteria are met, authorization may be granted for a 14 day period, followed by a 14 day drug-free period for initial treatment cycle.

II. RENEWAL CRITERIA

- Patient continues to meet the Initial Approval Criteria; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: hypersensitivity reactions, sulfite allergic reactions, etc.; **AND**
- Patient has responded to therapy compared to pretreatment baseline with disease stability or mild progression indicating a slowing of decline on the ALSFRS-R (patient has not experienced rapid disease progression while on therapy); **AND**
- Patient does not have a cumulative score on the ALSFRS-R of \leq 3

Dosage/Administration

Indication	Dose
ALS	60 mg (two consecutive 30 mg infusion bags) administered as an intravenous infusion over 60 minutes <ul style="list-style-type: none">– <u>Initial treatment cycle</u>: daily dosing for 14 days followed by a 14-day drug-free period– <u>Subsequent treatment cycles</u>: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods

Applicable Procedure Codes

J1301	Injection, edaravone, 1 mg
-------	----------------------------

Applicable NDCs

70510-2171-XX	Radicava 30 mg/100ml single dose bag
---------------	--------------------------------------

Applicable Diagnosis Codes

ICD-10	ICD-10 Description
G12.21	Amyotrophic lateral sclerosis

References

1. Radicava [package insert]. Jersey City, NJ; MT Pharma America, Inc; May 2017. Accessed February 2018.

2. Tanaka M, Sakata T, Palumbo J, et al. A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS). *Neurology* April 5, 2016 vol. 86 no. 16 Supplement P3.189.
3. Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014 Dec;15(7-8):610-7.
4. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *J Neurol Sci*. 1999 Oct 31;169(1-2):13-21.
5. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2009 Oct 13;73(15):1218-26.